60¢sixtycents

AbbVie Inc.ABBV

Is ABBV cheap right now? Every multiple below is scored against its own 10-year range, not a sector average.

$261.70+4.58 (+1.78%)24:00 UTC
NYSEHealthcareDividend King

Company snapshot

Market Cap
$463B
Mega-cap
+345%
2016 — today
10-Year Price
+310%
2016 — today
52-Week Range
$197.38$265.97
Current $261.70· 94%

AbbVie discovers, develops, and commercializes advanced biopharmaceuticals. Its portfolio spans: Immunology (HUMIRA, SKYRIZI, RINVOQ); Oncology (IMBRUVICA, VENCLEXTA); Virology (MAVYRET); Gastroenterology/Endocrinology (CREON, Synthroid, Linzess); Women’s Health/Urology (Lupron, ORILISSA); Neurology (Duopa, Ubrelvy, Botox); and Ophthalmology (Lumigan, Alphagan, Restasis). Spun off in 2012 and based in North Chicago, the firm maintains extensive research collaborations, including partnerships with Dragonfly Therapeutics.

Similar companies

Healthcare companies of comparable size to ABBV
CompanyP/EDiv yield
MRKMerck & Co., Inc.115.92.3%
UNHUnitedHealth Group Incorporated24.72.9%
JNJJohnson & Johnson30.32.0%
NVSNovartis AG21.03.4%
AZNAstraZeneca PLC24.62.0%
TMOThermo Fisher Scientific Inc.33.00.3%
LLYEli Lilly and Company38.20.6%
AMGNAmgen Inc.23.72.6%

Healthcare companies of comparable size — each one shown against its own 10-year range, not a sector average. Browse all stocks we cover.

Valuation in context

P/E ratio
73.7
Historically pricey
Historically pricey — last 10 years
Sector median 25.0above sector
P/B ratio
-78.7
N/A
Not meaningful — company is unprofitable
Sector median 2.5below sector
EV / EBITDA
24.9
Historically pricey
Historically pricey — last 10 years
Sector median 15.4above sector
Dividend Yield
2.6%
Near historic low
Near historic low — last 10 years
Sector median 1.7%above sector
FCF Yield
4.3%
Near historic low
Near historic low — last 10 years
Sector median -10.1%above sector
Free · No credit card needed

Get alerted when ABBV is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.